文献速递类风湿关节炎

类风湿关节炎生物/靶向合成改善病情抗风湿药减量的多中心随机非劣效试验

Outcomes of Tapering Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial.
PubMed 文献 · Arthritis Rheumatol · 2026-10-06

该24周多中心随机开放标签非劣效试验纳入348例持续低疾病活动度(LDA)的类风湿关节炎(RA)患者,比较b/tsDMARDs逐步减量vs继续治疗。符合方案集分析显示两组第24周维持LDA比例分别为88.2%和89.6%,风险差-1.43%(95%CI -8.09至5.23),达到预设非劣效界值-10%。结论为结构化减量在24周内维持疾病控制非劣于继续治疗。

要点

  • 持续LDA的RA患者中,b/tsDMARDs结构化减量24周维持LDA非劣于继续治疗。
  • 减量组88.2% vs 继续组89.6%维持LDA,风险差-1.43%(95%CI -8.09至5.23)。
  • 多数疾病恶化患者经方案指导重新升级治疗后可恢复LDA,无需永久停药。

核心结论

  • 在持续LDA的RA患者中,结构化b/tsDMARD减量策略在24周内维持疾病控制方面非劣于继续治疗。

研究设计与样本

  • 24周多中心随机开放标签非劣效试验,纳入接受稳定剂量b/tsDMARDs且DAS28-ESR定义LDA持续至少6个月的RA患者。
  • 348例患者随机分为继续治疗组(n=177)和减量组(n=171),主要终点为第24周维持DAS28-ESR LDA,非劣效界值预设为-10%。

主要发现

  • 符合方案集中,继续组和减量组分别有89.6%和88.2%维持LDA,风险差-1.43%(95%CI -8.09至5.23),满足非劣效标准。
  • 全分析集结果相似。
  • 多数疾病恶化患者在随访期间经方案指导重新升级治疗后恢复LDA,无需永久停药。
  • 多数次要结局组间相当,但部分疾病活动度指标有利于继续治疗,包括第12周DAS28-CRP及第24周DAS28-ESR和SDAI。
  • 两组不良事件均不常见。

关键数值与推荐

  • 主要终点:第24周维持DAS28-ESR定义的LDA。
  • 非劣效界值预设为-10%。
  • 符合方案集风险差-1.43%(95%CI -8.09至5.23)。

临床怎么用

  • 对已持续LDA至少6个月的RA患者,可考虑结构化b/tsDMARD减量策略,但需监测疾病活动度,恶化时按方案重新升级治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evidence supporting tapering of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD-tapering strategy in patients with RA who had achieved sustained LDA. METHODS: In this 24-week, multicenter, randomized, open-label, noninferiority trial, patients with RA receiving stable-dose b/tsDMARDs and maintaining Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR)-defined LDA for at least six months were randomized to either stepwise dose tapering or dose continuation. The primary endpoint was maintenance of DAS28-ESR LDA at week 24. The noninferiority margin was prespecified as -10%. Secondary endpoints included disease activity measures, remission rates, patient-reported outcomes, quality of life, and adverse events. RESULTS: A total of 348 patients were randomized to the continuation group (n = 177) or tapering group (n = 171). In the per-protocol population, LDA was maintained in 89.6% and 88.2% of patients, respectively, with a risk difference of -1.43% (95% confidence interval -8.09 to 5.23), meeting the prespecified criterion for noninferiority. Similar findings were observed in the full analysis set. Most patients experiencing disease worsening regained LDA after protocol-guided treatment reescalation during follow-up without permanent treatment discontinuation. Most secondary outcomes were comparable between groups, although some disease activity measures favored continuation, including DAS28 using the C-reactive protein level at week 12 and DAS28-ESR and Simplified Disease Activity Index at week 24. Adverse events were uncommon in both groups. CONCLUSION: In patients with RA with sustained LDA, structured b/tsDMARD tapering was noninferior to treatment continuation for maintaining disease control over 24 weeks.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Park DJ, Choi SE, Kang JH, et al. Outcomes of Tapering Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial. Arthritis Rheumatol. 2026. PMID: 42839723. doi:10.1002/art.70363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。